Safety concern regarding Rituxan in systemic lupus erythematosus

Systemic Lupus Erythematosus :: Safety concern regarding Rituxan in systemic lupus erythematosus

The Food and Drug Administration (FDA) is alerting health care professionals and patients treated with Rituxan (rituximab) to reports of an emerging risk of a serious side effect in patients receiving or who have used Rituxan.

FDA recently learned that two patients who were treated with Rituxan for systemic lupus erythematosus (SLE) developed progressive multifocal leukoencephalopathy (PML), a fatal viral infection of the central nervous system. This side effect has been reported in patients as late as 12 months after their last dose of Rituxan.

SLE is not an approved indication for Rituxan. Rituxan is approved only for the treatment of patients with non-Hodgkin's lymphoma and patients with rheumatoid arthritis whose disease no longer responds to other common treatments.

"Rituxan is used in both approved and off-label settings, and therefore it is very important for prescribers as well as patients to be aware of these new reports of the risk of PML," said Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research. "Patients who are being treated or have been treated with Rituxan who experience any major changes in vision, balance, or coordination, or who experience confusion, should promptly call their doctor."




(Systemic Lupus Erythematosus :: Safety concern regarding Rituxan in systemic lupus erythematosus published at SpiritIndia on Wednesday, December 20, 2006)

Systemic Lupus Erythematosus

Search more information on Systemic Lupus Erythematosus, Systemic Lupus Erythematosus books

Recently posted related articles on Systemic Lupus Erythematosus :

1. Systemic Lupus Erythematosus :: Safety concern regarding Rituxan in systemic lupus erythematosus
2. Systemic Lupus Erythematosus :: Interferon-regulated chemokines and SLE
3. Systemic Lupus Erythematosus :: Involvement of the amygdala in systemic lupus erythematosus
4. Lupus :: Epigenetic code n patients with systemic lupus erythematosus

Most related articles:

- Systemic Lupus Erythematosus :: Safety concern regarding Rituxan in systemic lupus erythematosus
- Systemic Lupus Erythematosus :: Involvement of the amygdala in systemic lupus erythematosus - 34
- Systemic Lupus Erythematosus :: Interferon-regulated chemokines and SLE - 33.7
- Lupus :: Epigenetic code n patients with systemic lupus erythematosus - 30.3
- Lupus :: Abnormal pap smears in women with lupus - 26.6
- Lupus :: Despite different triggers of disease, all roads lead to lupus - 24.4
- Lupus :: Immunosuppressive drug effective for reducing lupus flares - 20.5
- Lupus :: Over one-third of refractory lupus patients remain stable at long term follow-up - 19
- Lupus :: Safety of Oral Contraceptives in Women with Lupus - 18.5
- Lupus :: An Historical Aspect - 18.5

Systemic Lupus Erythematosus - recent related articles/news stories:

- Lupus drug Benlysta effective for SLE patients
- Genes linked with lupus giving hope for new treatments

»»   Breast Cancer :: Restoring tamoxifen sensitivity in resistant breast cancer cells
««   Pain :: FDA amends labeling changes to OTC Pain Relievers

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com